Rodman & Renshaw Begins Coverage on Athira Pharma (NASDAQ:ATHA)

Rodman & Renshaw started coverage on shares of Athira Pharma (NASDAQ:ATHA) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $22.00 price target on the stock.

Separately, JMP Securities restated a market outperform rating and set a $19.00 target price on shares of Athira Pharma in a report on Thursday, June 20th.

Athira Pharma Price Performance

Shares of NASDAQ ATHA opened at $3.32 on Monday. Athira Pharma has a fifty-two week low of $1.33 and a fifty-two week high of $4.30. The firm has a market capitalization of $127.06 million, a P/E ratio of -1.08 and a beta of 2.90. The company’s 50 day simple moving average is $2.95 and its 200 day simple moving average is $2.81.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. Sell-side analysts expect that Athira Pharma will post -2.79 EPS for the current fiscal year.

Insider Activity

In other Athira Pharma news, Director Kelly A. Romano acquired 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The shares were acquired at an average price of $2.26 per share, with a total value of $33,900.00. Following the purchase, the director now owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Athira Pharma news, Director Kelly A. Romano acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was acquired at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the transaction, the director now owns 53,315 shares of the company’s stock, valued at $120,491.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kelly A. Romano bought 27,400 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the completion of the purchase, the director now owns 80,715 shares in the company, valued at approximately $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Athira Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. raised its stake in shares of Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after purchasing an additional 3,333 shares during the period. Forefront Analytics LLC raised its position in Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after buying an additional 8,955 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Athira Pharma by 3.5% in the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after acquiring an additional 9,164 shares in the last quarter. Rothschild Investment LLC acquired a new position in Athira Pharma during the 2nd quarter worth approximately $34,000. Finally, Private Advisor Group LLC bought a new position in shares of Athira Pharma during the 4th quarter worth approximately $32,000. 57.12% of the stock is owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.